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Anxiety disorders represent a significant global health burden due
to their debilitating nature and high lifetime prevalence.1 They
frequently occur early and show high continuity into adulthood.2
Cognitive–behavioural therapy (CBT) is the most established
treatment option for childhood anxiety, with around 59% of
children remitting following treatment.3 The short, low-
expression allele of the functional serotonin transporter promoter
polymorphism, 5HTTLPR, has been associated with heightened
anxiety and related traits4 compared with the long allele, although
findings are somewhat mixed.5,6 Gene–environment interaction
studies provide evidence that short allele carriers have the poorest
outcomes in high stress environments,7 but also show the largest
benefit in response to low stress or enriching environments.8–11
These findings suggest that 5HTTLPR may represent a
‘differential susceptibility’ marker, which acts ‘for better and for
worse’.12 Some individuals who are more susceptible to the
negative effects of poor environments might also be more sensitive
to the positive effects of an enriching experience,13 and therefore
may respond better to the supportive influence provided by
psychological therapies. The field of ‘therapygenetics’ – genetic
predictors of outcome following purely psychological therapies –
is relatively new.14 In a previous study, we found that 5HTTLPR
genotype was significantly associated with CBT outcome.15 SS
homozygotes showed a significantly greater reduction in symptom
severity than long allele carriers, and were 20% (18.8%) more
likely to be free of their primary (all) anxiety disorder diagnoses
by follow-up. A handful of other studies have investigated
5HTTLPR and outcomes following a range of psychological
therapies, although results have not been consistent.15–23 Two
studies also found the SS genotype to be associated with more
positive outcomes; following a problem-solving intervention with
antidepressants in older adults with post-stroke depression,16 and
exposure-based therapy in adults with panic disorder with
agoraphobia.17 However, a third study examining CBT in post-
traumatic stress disorder found poorer outcomes in SS carriers.18
Additional studies in both adults and children found no effect of
5HTTLPR outcome following psychological interventions. Of
note, these studies are all of small sample size, and are generally
underpowered to detect what is likely to be a small effect of
5HTTLPR genotype. Furthermore, participants in many of the
studies were also on concurrent antidepressant or anxiolytic
medications. These factors highlight the need for replication in a
large sample to further examine the association between 5HTTLPR
genotype and outcome following a purely psychological therapy.
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Background
We previously reported an association between 5HTTLPR
genotype and outcome following cognitive–behavioural
therapy (CBT) in child anxiety (Cohort 1). Children
homozygous for the low-expression short-allele showed
more positive outcomes. Other similar studies have produced
mixed results, with most reporting no association between
genotype and CBT outcome.
Aims
To replicate the association between 5HTTLPR and CBT
outcome in child anxiety from the Genes for Treatment study
(GxT Cohort 2, n=829).
Method
Logistic and linear mixed effects models were used to
examine the relationship between 5HTTLPR and CBT
outcomes. Mega-analyses using both cohorts were performed.
Results
There was no significant effect of 5HTTLPR on CBT outcomes
in Cohort 2. Mega-analyses identified a significant association
between 5HTTLPR and remission from all anxiety disorders at
follow-up (odds ratio 0.45, P=0.014), but not primary anxiety
disorder outcomes.
Conclusions
The association between 5HTTLPR genotype and CBT
outcome did not replicate. Short-allele homozygotes
showed more positive treatment outcomes, but with small,
non-significant effects. Future studies would benefit from
utilising whole genome approaches and large, homogenous
samples.
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Based on our previous research, the aim of this study was to
test whether 5HTTLPR genotype was associated with outcome
following CBT in a large replication sample of 829 children with
anxiety disorders. This sample size far exceeded that required to
detect an effect of similar magnitude to that of our previously
reported findings, with greater than 95% power at a significance
level of a50.01. We hypothesised that children with the SS
genotype would (a) show greater rates of remission at follow-up
and (b) show a greater reduction in symptom severity at
follow-up than those with the SL or LL genotype. To further
increase power to detect an association between 5HTTLPR
genotype and outcome and to estimate an upper bound for the
magnitude of the effect, mega-analyses were performed on a
combined data-set comprising both our discovery (n=496) and
replication samples (n=829). Again, we hypothesised that SS
genotype carriers would show a more positive outcome following
treatment relative to SL or LL genotype carriers.
Method
Study overview
All participants come from the Genes for Treatment (GxT) study,
an international multisite collaboration designed to identify
clinical, demographic and genetic predictors of outcome following
CBT for child anxiety.24
Participants and treatment
Participants aged between 5 and 18 years (mean age: 10 years) met
DSM-IV criteria for primary diagnosis of an anxiety disorder.
Exclusion criteria included significant physical/intellectual
impairment, psychoses and concurrent treatment. All participants
completed a full course of CBT either as part of a trial or as
treatment as usual at one of 11 sites; Sydney, Australia (n=293);
Reading, UK (n= 199); Aarhus, Denmark (n=112); Bergen,
Norway (n=35); Bochum, Germany (n=50); Florida, USA
(n= 36); Basel, Switzerland (n=46); Groningen, The Netherlands
(n= 35); Oxford, UK (n= 11); Cambridge, UK (n= 9) and
Amsterdam, The Netherlands (n=3). All treatments were
manualised and treatment protocols across sites were comparable
for core elements of CBT, including teaching of coping skills,
cognitive restructuring and exposure. Treatment modalities fell
into three broad groups – individual CBT (39.8%), group-based
CBT (46.1%) and parent-supported guided self-help (14.1%).
Further sample characteristics and site-specific trial details can
be found in the online data supplement to this article.
Measures
Anxiety disorder diagnoses
Anxiety disorders were assessed at three time points; before and
after treatment, and at follow-up (3, 6 or 12 months after
conclusion of treatment). Diagnoses were made with the Anxiety
Disorders Interview Schedule for DSM-IV (ADIS-IV-C/P)25 at all
sites except for Bochum and Basel, where the German equivalent
(Kinder-DIPs) was used.26 Clinical severity ratings (CSRs) were
usually based on composite parent and child reports, and were
assigned on a scale of 0–8 (see Hudson et al24 for further details).
A diagnosis was made when the child met diagnostic criteria
and received a CSR of 4 or more. Primary diagnoses included
generalised anxiety disorder (GAD; 34.9%), separation anxiety
disorder (SAD; 25.1%), social anxiety disorder (20.8%), specific
phobias (11.9%), panic disorder (3.3%), obsessive–compulsive
disorder (OCD; 2.1%), post-traumatic stress disorder (PTSD;
1.3%), selective mutism (0.2%, in the cases with primary selective
mutism, a diagnosis of severe social phobia was also given; the
selective mutism was considered by the clinician to be primary,
the most interfering), and anxiety disorders not otherwise
specified (ADNOS; 0.5%).
Ethnicity
Ethnicity was determined by parent-report regarding the ancestry
of the child’s grandparents. Those with four grandparents of
reported White European ancestry were included in the ‘White
European subset’ (n= 560, see online data supplement).
Sample collection and genotyping
DNA samples were collected using either buccal swabs or Oragene
saliva kits (DNA Genotek, Ottawa, Canada) and extracted using
established procedures.27,28 5HTTLPR was genotyped using
polymerase chain reaction amplification and agarose gel electro-
phoresis according to published protocols.15 A selection of
samples (n= 40) were genotyped in duplicate, with consistent
results for each attempt. The genotypic distribution of the sample
conformed to Hardy–Weinberg proportions (LL: 25.9%, SL:
51.4%, SS: 22.7%; w21 = 0.69, P=0.444).
Ethical approval
All trials and collection of samples were approved by site-specific
human ethics and biosafety committees. Parents provided
informed consent, children assent. The storage and analysis of
DNA was approved by the King’s College London Psychiatry,
Nursing and Midwifery Research Ethics Sub-Committee.
Sample size and power analyses
Participants used in this paper are referred to as Cohort 2, which
consisted of 829 participants with clinical data available both at
baseline and at least one outcome time-point (post-treatment, a
follow-up time-point or both). However, of these, 792 had
outcome data at post-treatment; 606 at follow-up.
Power calculations29 suggested a sample size of 285 would be
required for 95% power to detect an effect of similar magnitude
to our previously reported findings (Cohort 1, odds ratio
(OR)= 0.4), at a significance level of a =0.01 using a recessive
allelic model. Our sample of 4600 has 490% power to detect
a smaller effect size (OR= 0.6) at a significance level of a =0.01,
and 80% power to detect an even smaller effect size of OR= 0.7
at a=0.05.
Data analysis
Definition of outcome variables
Treatment outcome was defined in a number of ways. Participants
were first classed as remitters or non-remitters based on the
presence or absence of their primary anxiety disorder diagnosis
(primary anxiety remission). Treatment remission was measured
both at post-treatment, and at follow-up (collapsed to include
all follow-up time-points; 3, 6 or 12 months). Remission was
also categorised as the absence of all anxiety disorder diagnoses
at post-treatment and at follow-up (all anxiety response). Finally,
treatment response was defined as the change in primary
anxiety disorder severity from pre- to post-treatment, and from
pre-treatment to follow-up.
Mixed effects models
To investigate the effect of 5HTTLPR genotype on remission,
logistic mixed effects models were used including treatment trial
as a higher order random effect. For consistency with the
statistical analyses used in our previous study, 5HTTLPR genotype
was defined by a recessive model, where SS was coded as 1
and SL/LL were coded as 0. Gender, age and baseline severity
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were included as covariates in all analyses (age and baseline
severity centred at the mean). Analyses were conducted for
primary anxiety diagnosis remission and all anxiety disorder
diagnoses remission separately at post-treatment and at follow-up.
Models focusing on the follow-up time-point included the linear
and quadratic effects of time as covariates.
Linear mixed effects models were used to investigate the effect
of 5HTTLPR genotype on response (change in primary anxiety
disorder severity). Again, trial was included as a higher order
random effect, and gender, age and baseline severity were included
as covariates. Time was included as a covariate for the model
testing change from pre- to post-treatment; and both linear and
quadratic effects of time were included as covariates in the model
for follow-up.
Mega-analyses
Finally, logistic and linear mixed models were run using parti-
cipants from both Cohort 115 and Cohort 2 combined. A total
of 584 samples were genotyped in Cohort 1, from children (aged
6–13) who received CBT for an anxiety disorder. In this sample,
496 had sufficient outcome data to be included in at least one
analysis. The sample size of 359 reported in Eley et al8 refers to
the White European participants included in the main analysis
of response to therapy at follow-up. Further participants were
included in analyses of response to therapy at post-treatment, with
a total of 496 included in at least one analysis. Participants
included in Cohort 1 were recruited at two sites: Sydney, Australia
and Reading, UK. Participants who were genotyped in Cohort 1
but whose clinical data were not available at the time of
submission were included in Cohort 2. Combining both cohorts
increased the sample size, and so the power to detect an
association between 5HTTLPR genotype and outcome. Cohort
was included as a covariate in these analyses.
Multiple testing corrections
For analyses of remission and response in the mega-analysis, we
applied a Bonferroni multiple testing correction to account for
the three outcome measures (primary anxiety remission, all
anxiety remission and treatment response), giving a corrected
significance level of P = 0.016. However, the outcome measures
used in this study are highly related and nested within each other,
and all analyses presented test the same core hypotheses; thus, the
correction is likely conservative.
All analyses were performed in STATA version 11.30
Results
Remission rates
Remission rates are given in Table 1 and were marginally higher
than in previous studies,3 with 61.1% of children remitting from
their primary anxiety disorder after treatment, and 71.8% by
follow-up. There were no significant differences between remitters
and non-remitters for age and gender (age: primary
t(604) =70.16, P=0.874; all anxiety t(570) =70.76, P=0.449;
gender: primary w21 = 0.42, P=0.515; all anxiety w
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1 = 0.47,
P= 0.492). Outcome data by genotype are also given in Table 1
for the additive model, and Fig. 1 shows outcomes for the reces-
sive model. Individuals with the SS genotype were 1.7% more
likely than those with SL/LL genotype to remit from their pri-
mary anxiety diagnosis and 6.5% more likely to remit from all an-
xiety diagnoses at follow-up. However, differences between the
groups were not statistically significant.
Logistic mixed effects models – predicting remission
No significant effect of genotype on treatment outcome was
detected for either primary or all anxiety diagnoses at post-treatment
(Table 2; primary: OR= 0.92, P= 0.551; all anxiety: OR= 1.09,
P=0.607); or at follow-up (Table 2; primary: OR=0.83, P=0.318;
all anxiety: OR= 0.66, P= 0.293). The odds ratio of less than 1
indicates that, as found previously, participants with the SS genotype
were more likely to remit than SL/LL children. A similar pattern of
effects was seen when analyses were restricted to the White
European subset (see Table DS1 in the online data supplement).
Change in symptom severity
Mean primary anxiety disorder severity at pre-treatment was 6.20
(s.d. = 1.05). At post-treatment, mean severity was 2.82
(s.d. = 2.12), corresponding with a change from pre-treatment of
3.39 (s.d. = 2.14; Table 1). Mean severity at follow-up was 2.15
(s.d. = 2.17) with a mean change from pre-treatment of 4.04
(s.d. = 2.21). There were no significant effects of age or gender
on change in symptom severity in Cohort 2 (age: b=70.01,
P=0.55; gender: b=0.04, P=0.53). Change in severity by genotype
is shown in Table 1 and Fig. 1(b). Participants with SS genotype
showed a marginally greater reduction in symptom severity by
post-treatment (0.10) and by follow-up (0.18) than SL/LL genotype
carriers but differences between the groups were not significant.
Linear mixed effects models – predicting response
No significant effect of genotype on change in primary diagnosis
symptom severity was detected, either during the course of
treatment (Table 2; pre-treatment to post-treatment: b=70.04,
P= 0.294) or at follow-up (pre-treatment to follow-up:
b=70.04, P= 0.318). This was also true of the White European
subset (online Table DS1). The overall standardised beta coefficient
of70.04 indicates that SS children had a 0.04 s.d. greater reduction
in severity scores than SL/LL children.
3
Table 1 Treatment outcome (response and remission) in Cohort 2 by 5HTTLPR genotype
Treatment outcome Time point Cohort 2 SS genotype SL genotype LL genotype
Primary anxiety disorder remissiona Post-treatment 61.1 63.7 59.2 62.6
Follow-up 71.8 73.1 72.3 69.5
All anxiety diagnoses remissiona Post-treatment 42.0 40.7 42.0 43.2
Follow-up 55.7 60.8 55.0 52.4
Primary anxiety disorder responseb Post-treatment 3.39 (2.14) 3.47 (2.13) 3.29 (2.14) 3.52 (2.16)
Follow-up 4.04 (2.21) 4.18 (2.16) 3.98 (2.21) 4.04 (2.24)
Comparisons between genotype groups are not statistically significant for any treatment outcome in Cohort 2.
a. Values for remission are the percentage free of primary and all anxiety disorder diagnoses at post-treatment and at follow-up.
b. Values for primary anxiety disorder response are the mean change in severity from the initial assessment at pre-treatment to the time point specified (s.d. in brackets).
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Mega-analyses
Before combining Cohorts 1 and 2 for analyses, the two cohorts
were compared for key variables. There were no significant
differences in gender distribution (w21 = 2.39, P= 0.122), treat-
ment modality (w22 = 4.07, P=0.131) or recessive genotype
(w21 = 1.98, P=0.159). Due to the recruitment from additional
studies in Cohort 2, a larger age range was included and Cohort
2 was significantly older (t(1271) = 5.15, P= 0.0001). Cohort 2 also
showed significantly higher rates of remission at post-treatment
(primary: w21 = 7.72, P= 0.005; all anxiety: w
2
1 = 7.35, P=0.007)
and at follow-up (primary: w21 = 7.24, P=0.007; all anxiety:
w21 = 13.60, P= 0.000).
In the entire sample (Cohorts 1 and 2 combined), SS
participants were 6.6% more likely to remit from their primary
anxiety disorder, and 11.4% more likely to remit from all anxiety
disorder diagnoses than SL/LL carriers (Fig. 1(c)). Additionally, SS
carriers showed a greater reduction in symptom severity from pre-
treatment to follow-up than SL/LL carriers (Fig. 1(d); SS:
change = 4.01, s.d. = 2.05; SL/LL: change = 3.79, s.d. = 2.19).
When using linear and logistic mixed effect models, the effect
of genotype on primary anxiety disorder response and remission
did not reach statistical significance (Table 3; change in CSR:
b=70.06, P= 0.070; remission: OR= 0.55, P= 0.095). However,
there was a significant effect of genotype on all anxiety diagnoses
remission (Table 3; OR= 0.45, P=0.014), which remained
nominally significant when multiple testing corrections were
made. In the White European subset, a similar pattern of results
was detected, although these did not reach statistical significance
(see online Table DS2).
Discussion
We attempted to replicate our previously reported association
between 5HTTLPR genotype and outcome following CBT. Our
replication sample comprised 829 children with a primary anxiety
diagnosis. We found no significant association between genotype
and remission of primary or all anxiety diagnoses at post-treatment
or follow-up time-points. Furthermore, change in primary anxiety
disorder symptom severity (response) across the course of
treatment did not differ as a function of 5HTTLPR genotype.
Mega-analyses combining data from this and our previous
report15 revealed a significant association between 5HTTLPR
genotype and remission of all anxiety disorders at follow-up.
Children carrying the SS genotype were more likely to be free of
all anxiety disorder diagnoses than children with the SL/LL
genotype. This effect remained significant after multiple testing
corrections.
In our previous paper, 20% (18.8%) more children with the SS
compared with SL/LL genotypes were free of their primary (all)
anxiety disorders at follow-up.15 The odds ratios were 0.39
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Fig. 1 Remission rates and response to cognitive–behavioural therapy (CBT).
Figure 1(a) shows the proportion of children free of their primary anxiety disorder and all anxiety diagnoses at follow-up, split by 5HTTLPR genotype in Cohort 2. Figure 1(b) shows the
change in primary anxiety symptom severity rating across the course of treatment by 5HTTLPR genotype in Cohort 2. Genotype was not significantly associated with any outcome
measure (P40.05 for all analyses). Figure 1(c) shows the proportion of children free of their primary anxiety disorder and all anxiety diagnoses at follow-up, split by 5HTTLPR genotype
in the combined sample. Figure 1(d) shows the change in primary anxiety symptom severity rating across the course of treatment by 5HTTLPR genotype in the combined sample.
Genotype was not significantly associated with primary anxiety remission or response (P40.05 for all analyses), but those homozygous for the short allele showed a significantly
greater remission for all anxiety disorders in the combined sample, even when clinical covariates were taken into account (*OR=0.45, P=0.014).
Non-replication of the association between 5HTTLPR and CBT response
(0.44) for primary (all) anxiety remission. In this study, the effects
observed were in the same direction but were markedly smaller
and non-significant. This overestimation of effect size within
discovery samples is often, at least in part, responsible for the
failure of subsequent studies to replicate genetic effects. This is
because replication studies are usually underpowered. This study
far exceeded the required N of 285 needed to detect an effect of
OR= 0.39 (as observed in our previous study) with 80% power
and a= 0.01. With a sample size of at least 600 in each analysis,
this study was sufficiently powered to detect an OR=0.39 with
greater than 99% power and a= 0.001. However, if the true effect
of 5HTTLPR in predicting CBT response is closer to the 0.66
observed in the present study, then this would require a sample
of N4900 to detect this effect at a=0.01 with 80% power (taking
into account the higher remission rate in the Cohort 2).
Mega-analyses are one means of increasing statistical power.
To this end, we examined the overall effect of 5HTTLPR genotype
on CBT outcome using all data available from this and our
previous paper. This allowed us to increase the available sample
size to n=1044. The effect of genotype on change in primary
anxiety disorder symptom severity was suggestive of an improved
response for SS genotype carriers but did not reach conventional
levels of significance. We found weak evidence of an association
between 5HTTLPR genotype and remission of all anxiety
diagnoses at follow-up, which was consistent with our previous
findings.15 SS genotype carriers were half as likely as SL/LL carriers
to retain any anxiety disorder diagnosis at follow-up (OR= 0.45).
The odds ratio for primary anxiety disorder remission was in the
same direction (OR= 0.55) but did not attain statistical
significance. These findings suggest that the 5HTTLPR genotype
accounts for only a very small amount of the variance in outcome
following CBT. Importantly, the 95% confidence intervals around
the OR of 0.45 (for all anxiety disorder remission) suggest that the
true effect size lies somewhere between 0.25 and 0.88 and thus
effectively provides an upper bound for estimating the effect of
5HTTLPR on remission following CBT. However, given the
tendency of early candidate gene discoveries to overestimate the
true effect, it remains highly plausible that the true effect may
in fact be nearer the lower bound estimate of 0.88 (a higher value
represents a smaller effect size with respect to these analyses; see
results section for further details). Future research attempting to
investigate outcome following psychological treatments as a
function of 5HTTLPR genotype should use this information when
making decisions regarding appropriate sample size.
The current paper adds to the expanding therapygenetics
literature investigating the 5HTTLPR polymorphism.14 Although
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Table 2 Mixed effect models; categorical remission and change in symptom severity at post-treatment and follow-up for primary
anxiety diagnosis; remission from all anxiety disorder diagnoses at post-treatment and follow-up
Remission Response – change in CSR
Primary anxiety disorder (n=792) All anxiety diagnoses (n=747) Primary anxiety disorder (n=788)
Time point OR 95% CI P OR 95% CI P b 95% CI P
Post-treatment
Genotype 0.92 0.71 to 1.20 0.551 1.09 0.79 to 1.48 0.607 70.04 70.11 to 0.03 0.294
Time 71.36 71.41 to 1.30 0.000
Baseline severity 1.15 1.03 to 1.29 0.013 1.22 1.07 to 1.39 0.003 0.29 0.26 to 0.32 0.000
Age 1.02 0.97 to 1.08 0.367 1.00 0.94 to 1.07 0.936 0.01 70.00 to 0.03 0.083
Gender 1.07 0.86 to 1.33 0.539 1.25 0.97 to 1.62 0.088 0.03 70.03 to 0.09 0.279
Primary anxiety disorder (n=606) All anxiety diagnoses (n=573) Primary anxiety disorder (n=581)
Time point OR 95% CI P OR 95% CI P b 95% CI P
Follow-up
Genotype 0.83 0.35 to 1.99 0.679 0.66 0.31 to 1.43 0.293 70.04 70.13 to 0.04 0.318
Time 0.00 0.00 to 0.01 0.000 0.00 0.00 to 0.02 0.000 71.03 71.09 to 0.97 0.000
Time2 2.72 1.76 to 4.19 0.000 2.27 1.64 to 3.13 0.000 0.15 0.13 to 0.16 0.000
Baseline severity 2.05 1.31 to 3.21 0.002 1.99 1.36 to 2.93 0.000 0.27 0.23 to 0.30 0.000
Age 0.96 0.80 to 1.14 0.631 1.02 0.88 to 1.20 0.750 0.00 70.02 to 0.02 0.957
Gender 0.79 0.39 to 1.62 0.523 1.20 0.64 to 2.23 0.569 0.03 70.04 to 0.10 0.461
CSR, clinical severity rating.
5HTTLPR genotype is defined using a recessive model, where SS= 1 and LL/LS = 0. Age and baseline severity are centered at the mean.
Table 3 Mega-analyses; results combining Cohorts 1 and 2. Outcome measures; primary anxiety disorder remission at
follow-up, change in primary anxiety CSR from pre-treatment to follow-up, all anxiety disorder diagnoses remission at follow-up
Remission Response – change in CSR
Primary anxiety disorder (n=1044) All anxiety diagnoses (n=1011) Primary anxiety disorder (n=1019)
Predictor variable at follow-up OR 95% CI P OR 95% CI P b 95% CI P
Genotype 0.55 0.27 to 1.11 0.095 0.45 0.25 to 0.88 0.014 70.06 70.13 to 0.01 0.070
Time 0.00 0.00 to 0.01 0.000 0.00 0.00 to 0.01 0.000 70.91 70.95 to 0.86 0.000
Time2 2.55 1.94 to 3.36 0.000 2.17 1.73 to 2.72 0.000 0.13 0.11 to 0.14 0.000
Baseline severity 2.05 1.44 to 2.91 0.000 2.30 1.63 to 3.23 0.000 0.27 0.24 to 0.29 0.000
Age 0.95 0.83 to 1.10 0.497 0.99 0.87 to 1.12 0.833 70.01 70.02 to 0.01 0.360
Gender 1.21 0.70 to 2.09 0.502 1.33 0.81 to 2.20 0.257 0.05 70.00 to 0.10 0.070
Cohort 0.65 0.33 to 1.27 0.206 0.55 0.30 to 1.02 0.056 70.05 70.12 to 0.01 0.100
CSR, clinical severity rating.
5HTTLPR genotype is defined using a recessive model, where SS= 1 and LL/LS = 0. Age and baseline severity are centred at the mean. Statistically significant results for genotype
are highlighted.
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this marker is a plausible candidate for involvement in outcome
following psychological therapy, 8 out of 11 studies have failed
to find a significant association between the 5HTTLPR and
treatment response, with the present study being by far the
most highly powered. The remaining studies observed mixed
effects: two studies16,22 found a significant association between
the SS genotype and a more positive treatment response, which
is consistent with the mega-analyses reported herein. However,
a third small study18 reported the opposite with the SS
genotype associated with fewer treatment gains. The weak and
contradictory findings seen thus far may reflect varying disorder
and treatment response phenotypes, the role of medication in
some studies and small, underpowered sample sizes.14
The use of a semi-structured diagnostic instrument to
characterise treatment outcome and agreement across study sites
on the definition of response are significant strengths of this study.
This study is also the largest to date to investigate genetic
predictors of outcome following psychological therapy. However,
there are some limitations. First, the sample is very heterogeneous,
including a range of anxiety diagnoses and several different CBT
modalities. One possibility is that the 5HTTLPR may have greater
predictive power when the sample and treatment is more
homogeneous.31 Second, the current study takes a candidate gene
approach. In all areas of psychiatric genetics, candidate gene
studies typically report very small effect sizes, often fail to replicate
and are sensitive to publication bias.32 To be able to nominate
candidate genes for investigation also requires a clear under-
standing of the pathophysiology of the phenotype under
investigation and the putative mechanisms through which
psychological therapies may act. We know that psychological
treatment response is a complex trait, thus it is very unlikely that
a single genetic polymorphism such as the 5HTTLPR will explain
a sufficiently large amount of variance in outcome to be clinically
meaningful in its own right. Although there remains a place for
adequately powered studies of plausible candidate genes within
the therapygenetics field, this challenge means it will become
increasingly important to move towards a whole-genome array-
based ‘therapygenomics’ approach. Whole-genome studies are
hypothesis free and thus have the potential to identify completely
novel and unexpected variants associated with psychological
treatment response. Perhaps, most importantly, there is the ability
to move beyond single variants and to identify groups of markers
and important biological pathways and systems, which collectively
capture a (clinically) significant proportion of the variance in
outcome. However, it is important to note that some genetic
variants (including the 5HTTLPR) cannot be adequately inferred
from array data and will continue to need to be genotyped
directly. Given the importance of clinical and demographic
predictors,24 optimal prediction of CBT response is likely to come
from analytic approaches, which aggregate genetic information
with clinical and demographic variables.33
In summary, this study failed to replicate our previously
reported association between 5HTTLPR genotype and outcome
following CBT for child anxiety disorders. Consistent with our
previous findings SS genotype carriers had a more positive
treatment response compared with SL/LL genotype carriers.
However, these effects were very small and mostly non-significant.
The increased sample size afforded by a mega-analytic approach
revealed a significant association between SS genotype and
remission of all anxiety disorders, which survived multiple testing
corrections. Importantly, this work provides an upper and lower
bound for estimating the effect size of association between
5HTTLPR and CBT outcomes, which are informative for other
researchers working in this area. Going forward, the therapy-
genetics field needs to embrace whole genome approaches and to
look to recruit large, homogenous samples in which to explore
genetic predictors of outcome following psychological therapies.
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Online supplement 
Sample characteristics and site specific trial details 
 
Unless otherwise specified, clinical trials included all primary anxiety disorder diagnoses. All 
sites made secondary anxiety disorder diagnoses where appropriate.  
Sydney, Australia (n = 293). Participants aged 6-18 were recruited from the Centre for 
Emotional Health, Macquarie University, Sydney. All participants completed the Cool Kids 
program (1), with 10-12 family sessions involving the parents (the majority of which were 
conducted in groups;  8% of the sample’s DNA were collected retrospectively). Variations on 
this treatment program include a subgroup from previous randomised trials who received 
group, individual or phone-based CBT sessions (2, 3); participants from a guided self-help 
trial with phone support for children in rural Australia (4); a group from a trial with additional 
parental anxiety management (5); and those recruited from an ongoing randomised trial of 
progressive allocation to treatment (Stepped Care).  
Reading and Oxford (n = 199), UK Participants aged 5-18 were recruited jointly from 
Reading and Oxford from eight trials at the Berkshire Child Anxiety Clinic (University of 
Reading) and the Oxfordshire Primary Child and Adolescent Mental Health Service. 
Participants received treatment in three main themes; one focussing on children with anxious 
mothers; a set of trials using a parent-guided self-help CBT program; and an online CBT 
program for adolescents.  
The Mother and Child (MaCh) project (6). Children whose mother also had a current anxiety 
disorder completed an 8 session manual-based CBT treatment based on the Cool Kids 
program (7). The mothers of these children also received extra sessions focussing on their 
own anxiety and on mother-child interactions.  
Overcoming. Children were treated with a parent-guided self-help CBT program, comprised 
of the same primary components as the Cool Kids program (7, 8). This consisted of 2-4 in-
person sessions and 2-4 telephone sessions.  A sub-set of this group with a primary anxiety 
disorder diagnosis of Social Phobia also received targeted Cognitive Bias Modification 
Training (CBM-I, (9)). Additionally, participants with highly anxious parents (screened using 
DASS or by meeting ADIS criteria) were randomised to groups in a trial including additional 
sessions for the parents which focussed on strategies for tolerating children’s negative 
emotions. In Oxford, treatment was based on the same basic program, and delivered by 
primary health workers as part of a feasibility trial (10). 
BRAVE. The final treatment group completed a therapist-supported online CBT program for 
adolescents (BRAVE), consisting of 10 sessions, half with 5 additional parent sessions and 
half without parent sessions.  
Aarhus, Denmark (n = 112). Participants aged 7-17 years were recruited from the 
Department of Psychology and Behavioural Sciences, Aarhus University, and all anxiety 
disorder diagnoses were included. Participants received CBT using the Cool Kids manual 
(including the adolescent version where appropriate (7, 11)). Participants came from two 
groups; one aged 7-17, from a trial including treatment and waitlist conditions; and another 
group aged 7-12 from a trial comparing efficacy of traditional group-based treatment with 
Cool Kids versus a guided self-help version with clinician support (bibliotherapy). In both 
trials only participants that received in-person CBT were included. 
Bergen, Norway (n = 35). Participants aged 5-13 were recruited from the child part of the 
“Assessment and Treatment – Anxiety in Children and Adults” study, Haukeland University 
Hospital, Bergen. Patients referred to outpatient mental health clinics in Western Norway, 
with a primary diagnosis of separation anxiety, social phobia, or generalized anxiety, 
received group or individual treatment with the FRIENDS program (4th edition (12, 13)) in a 
randomised control trial comparing active treatment with a waitlist condition  (14).  
Bochum, Germany (n = 50). Participants aged 5-18 were recruited from the Research and 
Treatment Centre for Mental Health, Ruhr-Universität Bochum. Participants received either 
exposure-based CBT (8-25 sessions, with sessions occurring at least every 2 weeks), the 
Coping Cat program (15), or a family-based  version of CBT specifically designed to target 
separation anxiety disorder (TAFF (16, 17)). Diagnoses were provided separately for parent- 
and child-report. The primary diagnosis was selected as being the most severe from either 
reporter. If the most severe disorder reported by each was of equal severity but was a 
different diagnosis, the parent-reported diagnosis was selected.  
Basel, Switzerland (n = 46).   Participants aged 5-13 (all with a primary diagnosis of 
Separation Anxiety Disorder) were recruited from the Faculty of Psychology, University of 
Basel. All participants took part in a randomised control trial comparing a family-based 
version of CBT specifically designed to target separation anxiety disorder (TAFF(16, 17)) 
with Coping Cat (15). All participants received 16 sessions over 12 weeks.  
Florida, USA (n = 36).  Participants aged 7 to 16 (including all primary anxiety disorder 
diagnoses except PTSD) were recruited from the Child Anxiety and Phobia Program, Florida 
International University, Miami. All participants received 12 to 14 hour-long sessions of 
individual manualised CBT. Additionally, two conditions included parental involvement 
focussing on different parent skills (Relationship Skills Training or Reinforcement Skills 
Training).  
Groningen, the Netherlands (n = 35).  Participants aged 8 to 17 were recruited from the 
Department of Child and Adolescent Psychiatry, University of Groningen. All participants 
were treated within  a randomised control trial of Coping Cat (Dutch version (18) including 
12 individual child sessions and 2 parent sessions. 
Cambridge, UK (n = 9). Participants aged 8-17 were recruited from the MRC Cognition and 
Brain Sciences Unit, Cambridge, UK. Participants were taking part in the ASPECTS trial, 
which recruited individuals exposed to a recent (i.e. in the previous six months) traumatic 
stressor (i.e. any event that involve the threat of death, severe injury, or threat to bodily 
integrity, or witnessing such an event). Those that developed PTSD were randomised to a 10-
week waitlist or individual PTSD-specific CBT (19), which consisted of up to 10 sessions 
over a 10 week period. Only participants that received treatment were included 
Amsterdam, the Netherlands (n = 3). Participants aged 10-14 were recruited from the 
Academic Treatment Centre for Parent and Child, University of Amsterdam UvA Minds and 
received either 12 weeks of CBT in individual sessions or 8 weeks of CBT in group sessions, 
according to the Dutch protocol Discussing + Doing = Daring (20). Diagnoses were provided 
separately for parent- and child-report with the primary diagnosis selected from these data by 
the trial manager.
 
Table DS1: White Subset Cohort 2 results; categorical remission and change in symptom severity at post-treatment and follow-up for primary anxiety 
diagnosis, and remission from all anxiety disorder diagnoses at post and follow-up.  
Note. 5HTTLPR genotype is defined using a recessive model, where SS=1 and LL/LS=0. Age and baseline severity are centred at the mean 
    Cohort 2 – White Subset 
Remission Response – Change in CSR 
Primary Anxiety Disorder (n = 550 ) All Anxiety Diagnoses (n = 516 ) Primary Anxiety Disorder (n = 529) 
Time-point Predictor Variable OR β β OR 95% CI P β 95% CI P 
Post-
Treatment 
Genotype 0.92 -0.06 -0.06 1.16 0.80-1.68 0.421 -0.06 -0.15-0.02 0.124 
Time     -1.37 -1.44--1.30 0.000 
Baseline severity 1.12 0.27 0.27 1.22 0.96-1.31 0.136 0.27 0.24-0.31 0.000 
Age 1.04 0.02 0.02 0.99 0.92-1.07 0.806 0.02 0.00-0.03 0.040 
Sex 1.13 0.04 0.04 1.41 1.03-1.92 0.030 0.04 -0.03-0.11 0.294 
 Primary Anxiety Disorder  (n = 442 ) All Anxiety Diagnoses  (n = 411 ) Primary Anxiety Disorder (n = 421) 
Time-point Predictor Variable OR β β OR 95% CI P β 95% CI P 
Follow-up 
Genotype 1.11 -0.01 -0.01 0.94 0.43-2.04 0.875 -0.01 -0.12-0.09 0.781 
Time 0.00 -1.09 -1.09 0.00 0.00-0.05 0.000 -1.09 -1.16--1.01 0.000 
Time2 2.61 0.16 0.16 2.19 1.53-3.12 0.000 0.16 0.14-0.18 0.000 
Baseline severity 1.84 0.24 0.24 1.82 1.22-2.70 0.003 0.24 0.20-0.28 0.000 
Age 0.91 -0.01 -0.01 1.01 0.86-1.19 0.889 -0.01 -0.03-0.02 0.621 
Sex 0.87 0.05 0.05 1.37 0.71-2.65 0.348 0.05 -0.03-0.13 0.240 
Table DS2: White Subset Mega-analyses; results combined Cohorts 1 & 2. Outcome measures; primary anxiety disorder remission at follow-up, change in 
primary anxiety CSR from pre-treatment to follow-up, all anxiety disorder diagnoses remission at follow-up 
Note. 5HTTLPR genotype is defined using a recessive model, where SS=1 and LL/LS=0. Age and baseline severity are centred at the mean 
 
 
White Subset Mega-analyses 
Remission Response – Change in CSR 
Primary Anxiety Disorder (n = 722) All Anxiety Diagnoses (n = 701) Primary Anxiety Disorder (n = 691) 
OR 95% CI P OR 95% CI P β 95% CI P 
Follow-up 
 
Genotype 0.58 0.25-1.32 0.52 0.52 0.25-1.07 0.074 -0.06 -0.14-0.02 0.140 
Time 0.00 0.00-0.01 0.00 0.00 0.00-0.02 0.000 -0.97 -1.03--0.92 0.000 
Time2 2.65 1.89-3.74 2.18 2.18 1.66-2.86 0.000 0.14 0.13-0.15 0.000 
Baseline severity 2.21 1.43-3.41 2.29 2.29 1.53-3.42 0.000 0.26 0.22-0.29 0.000 
Age 0.87 0.73-1.03 1.00 1.00 0.86-1.15 0.973 -0.01 -0.03-0.01 0.295 
Sex 1.28 0.67-2.44 1.66 1.66 0.93-2.97 0.085 0.08 0.02-0.15 0.010 
Cohort 0.66 0.30-1.47 0.49 0.49 0.24-0.99 0.047 -0.06 -0.14-0.02 0.116 
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